- Report
- February 2025
- 240 Pages
Global
From €2567EUR$2,690USD£2,151GBP
- Report
- March 2025
- 96 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 898 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 132 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 128 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- August 2024
- 233 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2662EUR$2,789USD£2,230GBP
- Report
- June 2024
- 185 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2024
- 395 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- August 2022
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- August 2022
- 115 Pages
Global
From €4295EUR$4,500USD£3,598GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more